Drugs / CV301
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02840994 | Dec 2016 → Jan 2020 | non-small cell lung carcinoma | Bavarian Nordic | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03315871 | Mar 2018 → Jun 2024 | prostate cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
Press releases naming this drug 7 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CV301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02840994 ↗ |
| Modality | Vaccine | “CV301, a poxviral-based vaccine” PMID 36054490 ↗ Sep 2022 |
| Route | Subcutaneous | “Administered subcutaneously.” NCT03315871 ↗ |